SCHEMBL4585510

SCHEMBL4585510

OC1(c2ccccc2)c2ccc(Br)cc2C(O)(c2ccccc2)c2cc(Br)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PDK2 Q15119 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
P2RX1 P51575 1/20 0.39
P2RX3 P56373 1/20 0.39
P2RX4 Q99571 1/20 0.39
P2RX7 Q99572 1/20 0.39
PIM1 P11309 1/20 0.36
CYP2A6 P11509 1/20 0.35
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824255 1.00 MEN1 (0.46) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL390934 0.98 PDK2 (0.45) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL29948098 0.98 PDK2 (0.45) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL13241717 0.90 PDK2 (0.45) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL12832339 0.90 MEN1 (0.40) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL25625063 0.90 MAP3K14 (0.41) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL12791350 0.88 MAPK1 (0.45) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL3038890 0.86 PDK2 (0.53) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL31483494 0.86 PDK2 (0.53) MEN1KMT2APDK2GABRA1GABRB2
SCHEMBL22633784 0.86 MEN1 (0.42) MEN1KMT2APDK2GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293381-B2 excellent power and luminance efficiencies in conjunction with a long service life; 2,7,9,10-tetraphenylanthracene SFC CO., LTD. (KR) 2012-10-23 US disclosed
US-8293381-B2 excellent power and luminance efficiencies in conjunction with a long service life; 2,7,9,10-tetraphenylanthracene SFC CO., LTD. (KR) 2012-10-23 US disclosed
US-8293381-B2 excellent power and luminance efficiencies in conjunction with a long service life; 2,7,9,10-tetraphenylanthracene SFC CO., LTD. (KR) 2012-10-23 US disclosed
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SFC CO., LTD. (KR) 2008-06-26 US disclosed
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SFC CO., LTD. (KR) 2008-06-26 US disclosed
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SFC CO., LTD. (KR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152950-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME C1S, C1R, AOC2 MEN1 923/4885KMT2A 3182/4885PDK2 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.